Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Robust Site-Directed Mutagenesis Kit Enables Standard and Novel Applications

By BiotechDaily International staff writers
Posted on 22 May 2013
A new kit that enables rapid site-directed mutagenesis (SDM) of plasmid DNA has been designed to include unique features that expand the range of applications, including a more effective method for introduction of long insertions and deletions. A new SDM primer design web tool that supports the kit has also been developed.

New England Biolabs (NEB; Ipswich, MA, USA) introduces the “Q5 Site-Directed Mutagenesis Kit,” capable of making standard single-base modifications as well as novel manipulations such as deletions or additions of almost any length, including for the addition of nuclear localization signals to cloned proteins. It also includes unique features for difficult-to-amplify GC-rich and repetitive sequences. "The Q5 SDM Kit makes applications possible for which you might not have thought of using SDM. For example, SDM can be a much quicker and less error-prone way to add tags, make large deletions, add or remove restriction sites, and many other sequence modifications," said John Pezza, PhD, scientist at NEB’s Applications and Product Development.

NEB adopted a nonoverlapping primer design to allow for longer modifications. The most popular SDM methods use overlapping primers that limit the length of insertions or deletions. NEB's approach enables exponential amplification and more efficient plasmid transformation, which also facilitates the successful modification of highly repetitive or GC-rich sequences. NEB has also released “NEBaseChanger,” an SDM primer design web tool that supports the Q5 SDM Kit. Developed by Sanjay Kumar, PhD, Senior Research Scientist at NEB, it includes a novel feature - the application of nearest neighbor thermodynamics for matched and mismatched bases to design mutational SDM primers and calculate custom annealing temperatures. "These adjustments increase the odds that the experiment will work. Most, if not all other design tools, are not able to take mismatches into account," said Dr. Pezza. NEBaseChanger also provides live primer design updates, so users can make iterative changes to their primers and watch how details like reading frame and Tm are affected.

The Q5 SDM Kit includes the robust Q5 Hot Start High-Fidelity Polymerase, which has been tested to amplify sequences with a fidelity 100-times greater than Taq and twice that of “Phusion” DNA Polymerase. The kit also includes high-efficiency NEB 5-alpha Competent E. coli. Robust results have been observed with plasmids up to at least 14 kb.

Related Links:

New England Biolabs
Q5 Site-Directed Mutagenesis Kit



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: A scheme for the generation of induced pluripotent stem cells (IPSC). (1) Isolate and culture donor cells. (2) Transfect stem cell-associated genes into the cells by viral vectors. Red cells indicate the cells expressing the exogenous genes. (3)  Harvest and culture the cells using mitotically inactivated feeder cells. (4) A small subset of the transfected cells forms iPSC cell colonies (Photo courtesy of Wikimedia Commons).

Innovative Technique Produces More Reliable Pluripotent Stem Cells

A recent paper described a more reliable way to induce the formation of pluripotent stem cells (iPSCs) from adult cells in a mouse model. Reliable high-quality iPSCs are needed for the development of... Read more

Drug Discovery

view channel
Image: S-649266 has more robust antibacterial activity than established antibiotics against multidrug-resistant bacteria (Photo courtesy of Shionogi).

Novel Antibiotic Shows Potential for Broad Range of Infections

The emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating the infection caused by multi drug resistant (MDR) bacteria. In order to treat bacterial... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.